HWGB and EBI CLINICAL STUDY CONFIRMED EFFICACY OF VACCINE TESTED FOR COVID-19 PREVENTION
2020-12-03 17:08:00
KUALA LUMPUR, 03 December 2020 - Ho Wah Genting Berhad (“HWGB†or the “Companyâ€) (Bursa Stock Code: 9601) today reports that its wholly owned subsidiary HWGB Biotech Sdn Bhd’s joint venture partner, US-based E-MO Biology Inc. (EBI) has proved that from its clinical study that polio booster vaccine in adults raises antibodies that will attack coronavirus.
The scientific research team led by Prof. Xie Qiyi (“Prof Xieâ€), a senior infectious disease expert that dedicated full-time on prevention of COVID-19. They were among the first to analyse the statistics on COVID-19 infections around the world. They confirmed that the COVID-19 infection rate of people under 30 years old in countries that have received oral poliovirus vaccine is much lower. From the difference in immunity of different vaccines, his team then analyzed the biological theory and found that the polio virus and the new coronavirus (SARS-CoV-2) share a similar structure of virus replication mRNA transferase. Thus, established the theoretical basis that the antibodies induced by the Polio vaccine can also inhibit the replication of the new coronavirus.
Prof. Xie's team submitted a paper and research project plan to demonstrate the correlation between COVID-19 and polio virus vaccine, of which had been approved by US Food and Drug Administration (“FDAâ€). The study is well underway now. It is proposed that we will be protected from COVID-19 with this vaccine.
What is the significance of FDA approval? The EMO’s vaccine clinical project was officially published on the US and WHO official clinical research webpage. This marks another progress in the project’s efforts to promote the prevention of COVID-19. The first is the FDA's recognition of EMO’s theoretical and practical implementation plans. In addition, a proven safe and effective vaccine with a solid 70 years of hospital use, will be repurposed to fight COVID-19.
The study help to better understand the pattern of the epidemics. It aims at looking for more evidence to indicate that the children's acquired immunity against SARS-CoV-2 through polio vaccination could set up the model for the benefit of the adult population in prevention against COVID-19.
Please refer to the US Food and Drug Administration website below for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
Ho Wah Genting Berhad (“HWGB†or the “Companyâ€) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group†or the “Groupâ€) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the ddistribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
E-Mo Biology Inc (“EBIâ€) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.
KUALA LUMPUR, 03 December 2020 - Ho Wah Genting Berhad (“HWGB†or the “Companyâ€) (Bursa Stock Code: 9601) today reports that its wholly owned subsidiary HWGB Biotech Sdn Bhd’s joint venture partner, US-based E-MO Biology Inc. (EBI) has proved that from its clinical study that polio booster vaccine in adults raises antibodies that will attack coronavirus.
The scientific research team led by Prof. Xie Qiyi (“Prof Xieâ€), a senior infectious disease expert that dedicated full-time on prevention of COVID-19. They were among the first to analyse the statistics on COVID-19 infections around the world. They confirmed that the COVID-19 infection rate of people under 30 years old in countries that have received oral poliovirus vaccine is much lower. From the difference in immunity of different vaccines, his team then analyzed the biological theory and found that the polio virus and the new coronavirus (SARS-CoV-2) share a similar structure of virus replication mRNA transferase. Thus, established the theoretical basis that the antibodies induced by the Polio vaccine can also inhibit the replication of the new coronavirus.
Prof. Xie's team submitted a paper and research project plan to demonstrate the correlation between COVID-19 and polio virus vaccine, of which had been approved by US Food and Drug Administration (“FDAâ€). The study is well underway now. It is proposed that we will be protected from COVID-19 with this vaccine.
What is the significance of FDA approval? The EMO’s vaccine clinical project was officially published on the US and WHO official clinical research webpage. This marks another progress in the project’s efforts to promote the prevention of COVID-19. The first is the FDA's recognition of EMO’s theoretical and practical implementation plans. In addition, a proven safe and effective vaccine with a solid 70 years of hospital use, will be repurposed to fight COVID-19.
The study help to better understand the pattern of the epidemics. It aims at looking for more evidence to indicate that the children's acquired immunity against SARS-CoV-2 through polio vaccination could set up the model for the benefit of the adult population in prevention against COVID-19.
Please refer to the US Food and Drug Administration website below for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
The scientific research team led by Prof. Xie Qiyi (“Prof Xieâ€), a senior infectious disease expert that dedicated full-time on prevention of COVID-19. They were among the first to analyse the statistics on COVID-19 infections around the world. They confirmed that the COVID-19 infection rate of people under 30 years old in countries that have received oral poliovirus vaccine is much lower. From the difference in immunity of different vaccines, his team then analyzed the biological theory and found that the polio virus and the new coronavirus (SARS-CoV-2) share a similar structure of virus replication mRNA transferase. Thus, established the theoretical basis that the antibodies induced by the Polio vaccine can also inhibit the replication of the new coronavirus.
Prof. Xie's team submitted a paper and research project plan to demonstrate the correlation between COVID-19 and polio virus vaccine, of which had been approved by US Food and Drug Administration (“FDAâ€). The study is well underway now. It is proposed that we will be protected from COVID-19 with this vaccine.
What is the significance of FDA approval? The EMO’s vaccine clinical project was officially published on the US and WHO official clinical research webpage. This marks another progress in the project’s efforts to promote the prevention of COVID-19. The first is the FDA's recognition of EMO’s theoretical and practical implementation plans. In addition, a proven safe and effective vaccine with a solid 70 years of hospital use, will be repurposed to fight COVID-19.
The study help to better understand the pattern of the epidemics. It aims at looking for more evidence to indicate that the children's acquired immunity against SARS-CoV-2 through polio vaccination could set up the model for the benefit of the adult population in prevention against COVID-19.
Please refer to the US Food and Drug Administration website below for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
Ho Wah Genting Berhad (“HWGB†or the “Companyâ€) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group†or the “Groupâ€) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the ddistribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
E-Mo Biology Inc (“EBIâ€) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.